Eli Lilly's Foundayo, Zepbound available to Medicare Part D enrollees on July 1
Seeking Alpha ·
Eli Lilly meds for obesity, Foundayo (orforglipron) and Zepbound (tirzepatide), will be available to certain Medicare Part D patients starting on July 1. Enrollees who meet Medicare GLP-1 Bridge Clinical Criteria and other CMS eligibility requirements can purchase the
DYAX Investor Sentiment
Bullish (Long) 62% · Bearish (Short) 38%
317 participants
Related News
- WisdomTree U.S. High Yield Corporate Bond Fund declares monthly distribution of $0.2250
- WisdomTree Premium Equity Income Fund declares monthly distribution of $0.3274
- WisdomTree High Income Laddered Municipal Fund declares monthly distribution of $0.0950
- Is SpaceX's $25B debt sale raising bubble concerns on Wall Street?
- Apple raises iPad and MacBook prices as AI pushes up costs
- Core & Main launches $750M senior notes offering